Acurx Pharmaceuticals Secures New Patent from Japanese Patent Office for DNA Polymerase IIIC Inhibitors, Expanding Antibiotic Development Program
Acurx Pharmaceuticals has been granted a new patent by the Japanese Patent Office for its DNA polymerase IIIC inhibitors, which target the treatment of MRSA, VRE, and Anthrax infections. This patent is set to expire in December 2039, subject to extension, and represents a significant advancement in the ongoing development of their pre-clinical antibiotic candidate, ACX-375C.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY85353) on May 13, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。